3,170 reports of this reaction
2.1% of all VENLAFAXINE reports
#7 most reported adverse reaction
COMPLETED SUICIDE is the #7 most commonly reported adverse reaction for VENLAFAXINE, manufactured by Alembic Pharmaceuticals Inc.. There are 3,170 FDA adverse event reports linking VENLAFAXINE to COMPLETED SUICIDE. This represents approximately 2.1% of all 151,835 adverse event reports for this drug.
VENLAFAXINE has an overall safety score of 88 out of 100. Patients taking VENLAFAXINE who experience completed suicide should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMPLETED SUICIDE is a less commonly reported adverse event for VENLAFAXINE, but still significant enough to appear in the safety profile.
In addition to completed suicide, the following adverse reactions have been reported for VENLAFAXINE:
The following drugs have also been linked to completed suicide in FDA adverse event reports:
COMPLETED SUICIDE has been reported as an adverse event in 3,170 FDA reports for VENLAFAXINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMPLETED SUICIDE accounts for approximately 2.1% of all adverse event reports for VENLAFAXINE, making it a notable side effect.
If you experience completed suicide while taking VENLAFAXINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.